Genedrive PLC (LON:GDR)

Genedrive PLC (LON:GDR)


Share Price
17.00 p
Change
-1.5 (-8.11 %)
Market Cap
£5.78 m
Proactive Investors - Run By Investors For Investors

Genedrive PLC

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. We are passionate about the opportunity to not only build a sustainable...

EPIC: GDR
Market: AIM:GDR
52-week High/Low: 31.900p / 17.000p
Sector: Pharma & Biotech
Market Cap: £5.78 m
Website: www.genedrive.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Genedrive PLC


Genedrive PLC Snapshot

Generdrive Overview

Molecular diagnostics at the point of need
Genedrive® is an innovative, easy to use platform that brings molecular diagnostics to decentralised laboratories.

Genedrive® is a patented small polymerase chain reaction (PCR) platform which enables rapid nucleic acid amplification and detection from various sample types including plasma, sputum and buccal swabs. With minimal hands on time and single button operation, it provides unambiguous diagnostic results, without the need for specialist knowledge or data interpretation. With no manual calibration or maintenance required, Genedrive® is ideal for low throughput, decentralised laboratories

Key Features

• Affordable platform that facilitates testing in low throughput settings.

• Decentralised testing

• Rapid results

• Single test throughput.

• Easy to use single button operation with simple software.

• For various sample types

• Single use consumables


Genedrive® Technology

The Genedrive instrument utilises proprietary Polymerase Chain Reaction (PCR) technology to rapidly amplify and detect target nucleic acid sequences without the requirement for nucleic acid isolation.

Following PCR amplification, melting curve analysis is used to establish the presence of the target sequence in the sample. Monitoring the changes in fluorescent signal intensity allows detection of specific RNA sequences. The final results are automatically interpreted by the Genedrive and displayed clearly on the instrument screen.

Each Genedrive HCV ID Kit consists of a lyophilised PCR reagent packaged into a single-use, disposable cartridge. The kit contains all the materials required for sample preparation and analysis.

For each assay an internal positive control (IPC) is included, which is used as an indicator for potential PCR inhibition. The time to result is assay dependant.

Genedrive® Connect

Genedrive® Connect. For Smarter Data Management.


Genedrive® Connect is our new* android based mobile app providing wireless data management to control your Genedrive network, manage patient data and transmit test results.

The phase 1 release of Genedrive® Connect is designed for efficient laboratory data management. It allows Genedrive® users to link patient demographics and user data, device and instrument data, and append this supplementary information to test results. The data record can then be transferred if needed to another location for patient management or data storage.

Genedrive® Connect will be available to download via Google Play on either a dedicated smartphone, or through an android BYOD (Bring Your Own Device) model. Following a user authentication and log in, the app automatically connects to Genedrive® instrument(s) via Bluetooth. The user can input or manage unique patient/specimen ID data. Final test results are uploaded via the Bluetooth connection. The results can then be transmitted using Wi-Fi or cellular network (email or SMS) and stored as needed. The patient results can also be sent directly to a clinician, via SMS, for immediate use in time sensitive treatment situations.

Subsequent phases of Genedrive® Connect are targeted to enable automated Genedrive® software updates, and provide market surveillance capabilities for treatment facilities, Health Agencies, and funding bodies.

United Kingdom.

Ian Gilham
Ph.D., Non-Executive Chairman

Ian was appointed a Director on 24 November 2014 and as Non-Executive Chairman on 11 May 2015. He is currently Non-Executive Chairman of three life sciences companies including AIM-quoted Horizon Discovery Group Plc, which provides gene-editing tools to support translational genomics and the development of personalised medicine, Elucigene, focussed on the development and commercialisation of laboratory based molecular diagnostic tests and Biosurfit SA, focussed on development and commercialisation of point-of-care diagnostic products. Dr Gilham was formerly Chief Executive Officer of Axis-Shield Plc.

David Budd
Chief Executive Officer

David was appointed a Director and Chief Executive on March 1, 2016. He has over 20 years of international commercial and operational experience in the diagnostics and medical devices field.  He previously served as General Manager of Leica Biosystems Amsterdam and Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, product development, and commercial launches for diagnostic tests. Prior to Leica, David’s roles included Point-of-Care, molecular, and central laboratory marketing and commercialisation responsibilities at Siemens Healthcare Diagnostics, Bayer Diagnostics, and Visible Genetics.

Matthew Fowler
Chief Financial Officer

Matthew was appointed Chief Financial Officer on December 13th 2016. He has over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes. Prior to that, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.

Tom Lindsay
Non-Executive Director

Tom has 35 years of global sales and marketing experience in the diagnostics sector. He most recently worked for Alere Inc. in Africa for 11 years before retiring in 2017.  At Alere he held a range of executive posts including President of Africa, President Commercial Operations for Africa, and Business Development Director for Africa; and led the introduction and successful commercialisation of a number of key HIV screening and HIV patient management point of care diagnostics technologies.

Prior to joining Alere Inc., Tom held senior commercial roles at Trinity Biotech (Ireland) including Marketing and Sales Director (Global) and Business Development Director for Africa, Middle East and India. Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits.

Tom studied Microbiology at Glasgow Caledonian University and completed a National Diploma in Microbiology at the South African Institute of Medical Research in Johannesburg, South Africa.

Chris Yates
Non-executive Director, Chairman of the Audit Committee

Chris was appointed to Board on 22 August 2018.  He is currently CEO of Abingdon Health, a position he has held since July 2015.  Chris co-founded Abingdon in 2008 and was a non-executive of the company prior to his appointment as CEO.  Chris has over 20 years experience of working in listed environments and prior to working at Abingdon, was CFO at Immunodiagnostic Systems Holdings PLC and Cozart plc.  Chris is a Chartered Accountant and has a degree in economics from Cambridge University.

Contact Details
genedrive plc
48 Grafton Street
Manchester
M13 9XX
UK

For further information:   [email protected]
Tel: +44 (0)161 989 0245
Fax: +44 (0)161 989 0262

Registered Office:
The Incubator Building
Grafton Street
Manchester
M13 9XX

Registered in England and Wales

Company No. 06108621

Company Secretary
Matthew Fowler
48 Grafton Street
Manchester M3 9XX

Principal Bankers
Natwest Commercial Banking
5th Floor, 1 Spinningfields Square
Deansgate
Manchester M3 3AP

Nominated Advisor and Broker
Peel Hunt LLP
120 London Wall
London
EC2Y 5ET

Registrars
Neville Registrars Limited
18 Laurel Lane
Halesowen
B63 3DA

Auditors
PriceWaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
101 Barbirolli Square
Lower Mosley Street
Manchester M2 3PW

Legal Advisors
Addleshaw Goddard LLP
Cornerstone
107 West Regent Street
Glasgow G2 2BA

Financial PR and Communications
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD

Investor Relations
Stanford Capital Partners Ltd
Head Office 15-17 Eldon Street
London
EC2M 7LD

Columns Including GDR

VIEW ALL

Market Reports Including GDR

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use